Flagship Pioneering, LLC Long-Term Concentrated

CIK: 0001400240 · Show all filings

Period: Q3 2019 (← Previous) (Next →)

Filing Date: Nov 14, 2019

Total Value ($000): $1,828,054 (100.0% shares, 0.0% debt)

Holdings (9)

MRNA Moderna Inc 51.2%

Value ($000) $936,213 Shares 58,807,379 Est. Cost $16.43 Unrealized -10.1%

— Rubius Therapeutics Inc 16.4%

Value ($000) $300,628 Shares 38,296,526 Est. Cost $24.00 Unrealized —

KLDO Kaleido Biosciences Inc 7.2%

Value ($000) $130,727 Shares 17,360,710 Est. Cost $13.76 Unrealized -36.9%

DNLI Denali Therapeutics Inc 6.7%

Value ($000) $122,648 Shares 8,005,747 Est. Cost $17.97 Unrealized +6.3%

— Evelo Biosciences Inc 6.1%

Value ($000) $111,224 Shares 18,233,403 Est. Cost $11.80 Unrealized —

— Seres Therapeutics Inc 4.7%

Value ($000) $86,502 Shares 21,571,764 Est. Cost $8.55 Unrealized —

TMDX TransMedics Group Inc 3.3%

Value ($000) $60,094 Shares 2,530,275 Est. Cost $27.30 Unrealized -12.2%

— Axcella Health Inc 2.7%

Value ($000) $49,516 Shares 8,748,414 Est. Cost $9.31 Unrealized —

— Syros Pharmaceuticals Inc 1.7%

Value ($000) $30,502 Shares 2,938,494 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	Moderna Inc	58,807,379	$936,213	51.2%	$16.43	-10.1%	COM	60770K107
—	Rubius Therapeutics Inc	38,296,526	$300,628	16.4%	$24.00	—	COM	78116T103
KLDO	Kaleido Biosciences Inc	17,360,710	$130,727	7.2%	$13.76	-36.9%	COM	483347100
DNLI	Denali Therapeutics Inc	8,005,747	$122,648	6.7%	$17.97	+6.3%	COM	24823R105
—	Evelo Biosciences Inc	18,233,403	$111,224	6.1%	$11.80	—	COM	299734103
—	Seres Therapeutics Inc	21,571,764	$86,502	4.7%	$8.55	—	COM	81750R102
TMDX	TransMedics Group Inc	2,530,275	$60,094	3.3%	$27.30	-12.2%	COM	89377M109
—	Axcella Health Inc	8,748,414	$49,516	2.7%	$9.31	—	COM	05454B105
—	Syros Pharmaceuticals Inc	2,938,494	$30,502	1.7%	$13.87	—	COM	87184Q107